Results 231 to 240 of about 66,883 (257)
Some of the next articles are maybe not open access.
Immune Checkpoint Inhibitors in Gliomas
Current Oncology Reports, 2017Malignant gliomas result in disproportionately high morbidity and mortality compared with other primary tumors, and progression of disease is inevitable. Novel therapies to improve outcomes are needed and immune checkpoint inhibitors hold significant promise.A limited body of preclinical evidence suggests that checkpoint inhibitors may be effective ...
Aaron C, Tan +2 more
openaire +2 more sources
Immune Checkpoint Therapy in Melanoma
The Cancer Journal, 2016Checkpoint-blocking antibodies have transformed cancer therapy, and the treatment of patients with metastatic melanoma has led the revolution. Herein, we review the current clinical data supporting the use of checkpoint-blocking antibodies in the treatment of melanoma and highlight outstanding clinical questions and unmet clinical needs.
openaire +2 more sources
Melanoma and Immune Checkpoint Inhibitors
Current Oncology Reports, 2018Prognosis of patients with advanced melanoma is dismal with a median overall survival of about 8 months and 5-year overall survival from a diagnosis of metastatic disease of roughly 10%. However, immune checkpoint inhibitors have brought indispensable benefits to melanoma patients.
Masutaka, Furue +5 more
openaire +2 more sources
Combined Immune Checkpoint Blockade
Seminars in Oncology, 2015There are very few tumor types for which chemotherapy regimens are regularly curative; notable exceptions include testicular cancer and Hodgkin's lymphoma. In both cases combination chemotherapy approaches are required. Thus, it would seem only logical that combination immunotherapy approaches will be required to induce long-term remissions in the ...
openaire +2 more sources
The future of immune checkpoint therapy
Science, 2015Immune checkpoint therapy, which targets regulatory pathways in T cells to enhance antitumor immune responses, has led to important clinical advances and provided a new weapon against cancer. This therapy has elicited durable clinical responses and, in a fraction of patients, long-term remissions where patients exhibit no clinical signs of cancer for ...
Padmanee, Sharma, James P, Allison
openaire +2 more sources
Targeting immune checkpoints in lymphoma
Current Opinion in Hematology, 2015The purpose of this article is to discuss the tumor microenvironment in lymphoma, and to review potential immune targets that are now becoming relevant because of clinical responses seen with the use of immune checkpoint inhibitors.Recent data have shown that cells within the immune microenvironment in lymphoma express programmed death ligand-1 (PD-L1)
openaire +2 more sources
Checkpoints in antibacterial immunity
Research in Immunology, 1998Flesch, I. +3 more
openaire +3 more sources